The latest research from Omdia shows that PC shipments (excluding tablets) to the United States fell 1% year-on-year in Q3 2025 to 17.7 million units, marking the second consecutive quarter of decline. Despite noticeable downward macroeconomic pressures, the consumer segment grew 8% in the quarter to 7.6 million units. The commercial segment was broadly stable, with shipments declining by just under 1%, while the education and government segments together saw a sharper 23% drop in Q3. Even with...

Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced the development of a nanoimprint lithography (NIL) template featuring a circuit line width of 10 nanometers (nm: 10-9 meter). The new template enables patterning for logic semiconductors equivalent to the 1.4nm generation and meets the miniaturization needs of cutting-edge logic semiconductors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208175160/en/Template for n...

Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced the expansion of Airtel Mobile Money as a local payment method to include Tanzania and Madagascar. This growth builds on Xsolla’s existing Airtel Mobile Money coverage in Africa, extending secure, mobile-first checkout experiences to more players in two of the continent’s rapidly digitalizing markets. This press release features multimedia. View the full release here: https...

TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their role...

Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indi...